Resource Centre

Endevica Bio is developing TCMCB07 as a novel synthetic peptide product for the potential treatment of cachexia. Read how they leveraged the Quotient Sciences Translational Pharmaceutics platform for this program.

Request a copy of our latest case study with Ensysce Biosciences about how our integrated strategies helped them achieve their regulatory milestones faster for PF614-MPAR, an Extended Release product.

Quotient Sciences seeking to improve the yield and purity of a US Biotech API intermediate using flow chemistry

Rapid development of a scalable route towards an analogue of a new drug substance, with definition of an optimal salt form for formulation

UK specialty-pharma company in need of biochemical assay for their regulatory non-clinical safety study

Multiple, biotechnology and large-pharma companies needing isotope labelling support for their ADME/hAME studies

US biopharmaceutical company seeking to improve stability of their chemically unstable API intermediate for radiochemical trials

UK Clinical Research Unit (CRU), developing intravenous (IV) products in need of analytical & microbiological support

European biotech company developing an NCE to fulfil an unmet patient need, required insulin analogue analysis to gain regulatory approval

US Biopharmaceutical seeking drug substanceand salt screen selection for their molecule.

US Biotech wanted to determine the DCS (Developability Classification System) designation for their small molecule. This included project scope and outcomes of the project.

Druggability Technologies (DRGT) was developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, the former CEO of DRGT, explains how we enabled the rapid development, clinical assessment and commercial readiness of its drug product using integrated services across sites in the UK and the US.